Latest

Bristol-Myers Squibb sales rise, Opdivo dominates PD-1 market

Bristol-Myers Squibb sales rise, Opdivo dominates PD-1 market

Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.

Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

Sales of the new cancer drug topped expectations since its February launch.

Medtronic agrees to consent decree

The manufacturer's SynchroMed drug-infusion pump was associated with 14 deaths.

PCSK9 antibodies are safe and effective, analysis concludes

PCSK9 antibodies reduced overall mortality and lowered LDL cholesterol levels in more than 10,000 patients in Phase-II/III clinical trials.

Five things for pharma marketers to know: Tuesday, April 28

Five things for pharma marketers to know: Tuesday, April 28

Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid

FDA says Amgen cancer data can't support accelerated approval

FDA says Amgen cancer data can't support accelerated approval

Briefing materials released before Wednesday's panel review indicate the regulator wants clearer data to assess Amgen's experimental melanoma treatment.

Apple Watch — do you love it?

We know it's early days (the smartwatch been available for three days to be exact), but we'd like to know how it is going.

Open Payments database draws 1M visitors

The Centers for Medicare and Medicaid Services last year published 4.45 million records about financial relationships between industry and HCPs.

Five things for pharma marketers to know: Monday, April 27

Five things for pharma marketers to know: Monday, April 27

More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market

Agency Spotlight


The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters